NSC 631570
Alternative Names: NSC B238865; Ukrain; UKSR 222; W122Latest Information Update: 04 Nov 2017
At a glance
- Originator Nowicky Pharma
- Developer Military Medical Academy; Nowicky Pharma; Ukrainian Anti-Cancer Institute
- Class Antineoplastics; Berberine alkaloids; Phenanthridines
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Cancer
- No development reported Influenza virus infections; Pancreatic cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Combination therapy, Late-stage disease) in Germany (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(Combination therapy, Late-stage disease) in Ukraine (IV, Infusion)
- 10 Oct 2002 A study has been added to the adverse events and Cancer therapeutic trials sections